Correlation Between Surrozen and RenovoRx
Can any of the company-specific risk be diversified away by investing in both Surrozen and RenovoRx at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Surrozen and RenovoRx into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Surrozen and RenovoRx, you can compare the effects of market volatilities on Surrozen and RenovoRx and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Surrozen with a short position of RenovoRx. Check out your portfolio center. Please also check ongoing floating volatility patterns of Surrozen and RenovoRx.
Diversification Opportunities for Surrozen and RenovoRx
Weak diversification
The 3 months correlation between Surrozen and RenovoRx is 0.31. Overlapping area represents the amount of risk that can be diversified away by holding Surrozen and RenovoRx in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on RenovoRx and Surrozen is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Surrozen are associated (or correlated) with RenovoRx. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of RenovoRx has no effect on the direction of Surrozen i.e., Surrozen and RenovoRx go up and down completely randomly.
Pair Corralation between Surrozen and RenovoRx
Given the investment horizon of 90 days Surrozen is expected to generate 1.21 times more return on investment than RenovoRx. However, Surrozen is 1.21 times more volatile than RenovoRx. It trades about -0.03 of its potential returns per unit of risk. RenovoRx is currently generating about -0.09 per unit of risk. If you would invest 1,346 in Surrozen on December 30, 2024 and sell it today you would lose (245.00) from holding Surrozen or give up 18.2% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Surrozen vs. RenovoRx
Performance |
Timeline |
Surrozen |
RenovoRx |
Surrozen and RenovoRx Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Surrozen and RenovoRx
The main advantage of trading using opposite Surrozen and RenovoRx positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Surrozen position performs unexpectedly, RenovoRx can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in RenovoRx will offset losses from the drop in RenovoRx's long position.Surrozen vs. Bolt Biotherapeutics | Surrozen vs. Larimar Therapeutics | Surrozen vs. Keros Therapeutics | Surrozen vs. Kezar Life Sciences |
RenovoRx vs. Adial Pharmaceuticals | RenovoRx vs. Pasithea Therapeutics Corp | RenovoRx vs. Quoin Pharmaceuticals Ltd | RenovoRx vs. Nutriband |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Complementary Tools
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Fundamental Analysis View fundamental data based on most recent published financial statements |